5 Курс / Гастроэнтерология / R_FD2016
.pdf41
37.Müller-Lissner S., Koelz H.R. Dyspepsiefibel. – Berlin-Heidelberg-New York. – 1991. – 67 S.
38.Nimmuan C., Rabe-Hesketh S., Wessely S., Hotopf M. How many functional somatic syndromes? // J.Phychosom.Res. – 2001.–Vol.51. – P.549-557.
39.Nyren O., Adami H.-O, Gustavsson S. et al. Social economic effects of non-ulcer dyspepsia // Scand.J.Gastroenterol.–1985.–Vol.20.- Suppl.109.–P.41-4
39а. Ottilinger B., Storr M., Malfertheiner P., Allescher H.-D STW 5 (Iberogast®) – a safe and effective standart in the treatment of functional gastrointestinal disorders . Wien. Med. Wochenschr. 2013; 163: 65-72.
40.Peura D. Meeting expectations in FD: clinical and regulatory objectives.
Clinician’s viewpoint // Functional dyspepsia: current evidence and cutting edge
outcomes . - Abstract book. – Montreal, 2005. – P.16-18
41.Samson M., Verhagen M.A., van Berge-Henegouwen G.P. et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. – Gastroenterology. – 1999. – Vol.116.
–P.515-520.
42.Sarnelli G., Caenepeel Ph., Geypens B. et al. Symptoms associated with impared gastric emptying of solids and liquids in functional dyspepsia // Amer.J.Gastroenterol. – 2003. – Vol.98. – P.783-788.
43.Sarnelli G., De Giorgi F., Atteo E. et al. Frequency, symptom evolution and pathophysiological correlates in prospectively identified patients with postinfectious dyspepsia // DDW – New Orleans, 2010. – Abstract M2010.
44.Sawant P. , Das H.S., Desai N et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia // JAPI. – 2004 – Vol.52. - P.626-628.
45.Soo Sh., Forman D., Delaney C., Moayyedi P. A systemic review of psychological therapies for nonulcer duspepsia // Amer. J.Gastroenterol. – 2004. –
Vol.99. – P.1817-1822.
42
46.Stanghellini V., Tosetti C., Paternico A. et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia // Gastroenterology. – 1996. – Vol.110. – P.1036-1042.
46а. Stanghellini V., Chan F.C.L., Hasler W.L. et al. Gastroduodenal disorders. Gastroenterology 2016; 150 (6): 1380-1392.
46б. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 133-167.
47.Tack J., Talley N.J., Camilleri M. et al. Functional gastroduodenal disorders // Gastroenterology. – 2006. – Vol.130. – P. 1466-1479.
48.Tack J. Piessevaux H., Coulie B et al. Role of impaired gastric accommodation to a meal in functional dyspepsia // Gastroenterology. – 1998. –
Vol.115. – P.1346-1352.
49. Tack J., Caenepeel P., Fischler B. et al. Symptoms associated with hypersensitivity to gastric distension in functional dyspepsia // Gastroenterology. – 2001. – Vol.121. – P.526-535
50.Talley N.J. and the working team for functional gastroduodenal disorders. Functional gastroduodenal disorders // In: The functional gastrointestinal disorders. – Boston – New York-Toronto-London, 1994. – P.71-113.
51.Talley N.J., Helgeson S.L., Zinsmeister A.R. et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based-study // Gastroenterology. –
1994 .- Vol.107. – P.1040-1049.
52. Talley N.J., Janssens L., Lauritsen K. et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 month follow up // Br.Med.J. – 1999. – Vol.318. – P.833-837.
53. Talley N.J., Meineche-Schmidt V., Pare P. et al. Eficacy of omeprazole im functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies) //Aliment. Pharnacol. Ther.–1998.–Vol.12.–P.1055-1065.
43
54.Talley N.J., Stanghellini V., Heading R.C. et al. Functional gastroduodenal disorders // Rome II. The Functional Gastrointestinal Disorders (Ed D.A.Drossman).- 2. Edition. – Allen Press. – 2000. – P.299-350.
Talley N.J., Locke G.R., Saito Y.A. et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology 2015; 149: 340-349.
55.Tominaga K., Suzuki H., Umegaki E. et al. Rabeprazole imprоves the symptoms of functional dyspepsia – a double-blind randomized placebo-controlled multi-center trial in Japan: The CAESAR study // DDW – New Orleans, 2010. –
Abstract 383.
56. Van Lelyveld N., Scheffer R,., Mundt M., Samson M. Partial gastric volumes and upper abdominal sensations in functional dyspeptic and GERD patients: a 3D ultrasonographic study // Amer.J.Gastroenterol. – 2006. – Vol.101. – P.1845-1852.
57.Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., Talley N.J. Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis // Am.J.Gastoenterol. – 2001. – Vol.96. – P.689-696.
58.Warrwewijk C.J., Van Oijen M.G.H., Paloheimo L.I. et al. Influence of gastric mucosal status on successs of stepwise acid suppressive therapy for dyspepsia // Aliment.Pharmacol.Ther. – 2009. – Vol.30. – P.82-89.
59.Wilhelmsen I., Haug T., Sipponen P., Berstad A. Helicobacter pylori in functional dyspepsia // Scand.J.Gastroenterol. – 1994. – Vol.29. – P.522-527.